, sex and

Cerebral beta-amyloid (A  ) accumulation is the earliest detectable pathophysiological event along the Alzheimer’s disease (AD) continuum , therefore an accurate quantification of incipient A  abnormality is of great importance to identify preclinical AD. Both cerebrospinal fluid (CSF) A  concentrations and Position Emission Tomography (PET) with specific tracers provide established biomarkers of A  pathology. Yet, they identify two different biological processes reflecting the clearance rate of soluble A  as opposed to the cerebral aggregation of insoluble A  fibrils. Studies have demonstrated high agreement between CSF and PET-based A  measurements on diagnostic and prognostic levels. However, an open question is whether risk factors known to increase AD prevalence may promote an imbalance between these biomarkers, leading to a higher cumulative A  cerebral aggregation for a given level of cleared A  in the CSF. Unveiling such interactions in cognitively unimpaired (CU) individuals shall provide novel insights into the biological pathways underlying A  aggregation in the brain and ultimately improve our knowledge on disease modelling. With this in mind, we assessed the impact of three major unmodifiable AD risk factors (age, APOE -  4 and sex) on the association between soluble and deposited A  in a sample of 293 middle-aged CU individuals who underwent both lumbar puncture and PET imaging using the [ 18 F]flutemetamol tracer. We looked for interactions between CSF A  42/40 concentrations and each of the assessed risk factors, in promoting A  PET uptake both in candidate regions of interest and in the whole brain. We found that, for any given level of CSF A  42/40, older age and female sex induced higher fibrillary plaque deposition in neocortical areas including the anterior, middle and posterior cingulate cortex. By contrast, the modulatory role of APOE -  4 was uniquely prominent in areas known for being vulnerable to early tau deposition, such as the entorhinal cortex and the hippocampus bilaterally. Post hoc three-way interactions additionally proved evidence for a synergistic effect among the risk factors on the spatial topology of A  deposition as a function of CSF A  levels

[1]  W. M. van der Flier,et al.  Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype , 2020, Neurology.

[2]  Mark E. Schmidt,et al.  Multitracer model for staging cortical amyloid deposition using PET imaging , 2020, Neurology.

[3]  Jesse A. Brown,et al.  Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET , 2020, Science Translational Medicine.

[4]  Muhammad Naveed Iqbal Qureshi,et al.  Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. , 2019, JAMA neurology.

[5]  Philip S. Insel,et al.  Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease , 2019, EMBO molecular medicine.

[6]  O. Hansson,et al.  Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. , 2019, JAMA neurology.

[7]  M. Weiner,et al.  APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points. , 2019, Journal of Alzheimer's disease : JAD.

[8]  K. Blennow,et al.  Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease , 2019, Molecular and Cellular Neuroscience.

[9]  J. Leal,et al.  The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study , 2019, NeuroImage: Clinical.

[10]  K. Blennow,et al.  Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers , 2019, Alzheimer's Research & Therapy.

[11]  Alan C. Evans,et al.  Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease , 2019, bioRxiv.

[12]  A. Fagan,et al.  Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging , 2018, Alzheimer's & Dementia.

[13]  C. Jack,et al.  Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology , 2018, Alzheimer's & Dementia.

[14]  N. Pedersen,et al.  Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.

[15]  for the Alzheimer’s Disease Neuroimaging Initiative,et al.  Sex differences in Alzheimer disease — the gateway to precision medicine , 2018, Nature Reviews Neurology.

[16]  Yi Su,et al.  Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &egr;4 genotype , 2018, Brain : a journal of neurology.

[17]  B. Borroni Faculty of 1000 evaluation for PET imaging of tau deposition in the aging human brain. , 2018 .

[18]  A. Ripka Faculty of 1000 evaluation for Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. , 2018 .

[19]  Bin Zhang,et al.  Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation , 2017, Nature Medicine.

[20]  Daniel R. Schonhaut,et al.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.

[21]  Clifford R. Jack,et al.  Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum , 2017, Cortex.

[22]  J. Sepulcre,et al.  In vivo staging of regional amyloid deposition , 2017, Neurology.

[23]  Henrik Zetterberg,et al.  Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity , 2017, Nature Communications.

[24]  Philip S. Insel,et al.  Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations , 2017, Alzheimer's Research & Therapy.

[25]  T. Montine,et al.  Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults , 2017, Alzheimer's Research & Therapy.

[26]  Pedro Rosa-Neto,et al.  Synergistic interaction between amyloid and tau predicts the progression to dementia , 2017, Alzheimer's & Dementia.

[27]  H. Vanderstichele,et al.  Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition , 2017, Alzheimer's & Dementia.

[28]  Christopher C Rowe,et al.  Biochemically-defined pools of amyloid-&bgr; in sporadic Alzheimer’s disease: correlation with amyloid PET , 2017, Brain : a journal of neurology.

[29]  M. Mintun,et al.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.

[30]  Ming-Rong Zhang,et al.  Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study , 2016, Alzheimer's & dementia.

[31]  Johannes Kornhuber,et al.  Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease , 2016, Journal of Alzheimer's disease : JAD.

[32]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[33]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[34]  Paul M. Thompson,et al.  Age, APOE and sex: Triad of risk of Alzheimer’s disease , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[36]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[37]  J. Molinuevo,et al.  The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease , 2016, Alzheimer's & dementia.

[38]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[39]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[40]  K. Blennow,et al.  Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease , 2015, Neurology.

[41]  P. Albert,et al.  Why is depression more prevalent in women? , 2015, Journal of psychiatry & neuroscience : JPN.

[42]  E. Cadenas,et al.  Perimenopause as a neurological transition state , 2015, Nature Reviews Endocrinology.

[43]  C. Jack,et al.  Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. , 2015, JAMA neurology.

[44]  Russell A. Poldrack,et al.  Orthogonalization of Regressors in fMRI Models , 2015, PloS one.

[45]  P. Snyder,et al.  APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease , 2015, Neurobiology of Aging.

[46]  Philip S. Insel,et al.  Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. , 2015, Brain : a journal of neurology.

[47]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[48]  J. Clarimón,et al.  Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease , 2014, Annals of neurology.

[49]  Philip S. Insel,et al.  Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease , 2014, Annals of clinical and translational neurology.

[50]  Rebecca A Betensky,et al.  Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease , 2014, Neurology.

[51]  Andre Altmann,et al.  Sex modifies the APOE‐related risk of developing Alzheimer disease , 2014, Annals of neurology.

[52]  S. Engelborghs,et al.  Biobanking of CSF: international standardization to optimize biomarker development. , 2014, Clinical biochemistry.

[53]  M. Mintun,et al.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.

[54]  M. Staufenbiel,et al.  Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein , 2013, Science Translational Medicine.

[55]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[56]  Henrik Zetterberg,et al.  Fluid biomarkers in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[57]  A. Dale,et al.  Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. , 2012, Archives of neurology.

[58]  Denise C. Park,et al.  &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.

[59]  C R Jack,et al.  Spotlight on the January 24 Issue , 2012, Neurology.

[60]  A. Drzezga,et al.  Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.

[61]  K. Blennow,et al.  The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease , 2009, Neurobiology of Aging.

[62]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[63]  Keith A. Johnson,et al.  Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.

[64]  S. Rombouts,et al.  Reduced resting-state brain activity in the "default network" in normal aging. , 2008, Cerebral cortex.

[65]  R. Sperling,et al.  Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation , 2008, Proceedings of the National Academy of Sciences.

[66]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[67]  L. Launer The epidemiologic study of dementia: a life-long quest? , 2005, Neurobiology of Aging.

[68]  L. Thal,et al.  Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease , 2004, Neurology.

[69]  J. Wesson Ashford,et al.  ApoE genotype accounts for the vast majority of AD risk and AD pathology , 2004, Neurobiology of Aging.

[70]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[71]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[72]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[73]  E M Wijsman,et al.  Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease , 1995, Neurology.

[74]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[75]  B. Hyman,et al.  Synergy between amyloid-beta and tau in Alzheimer’s Disease , 2020 .

[76]  S. O'Bryant,et al.  Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[77]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[78]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[79]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.